MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Critical Care

Septic Shock in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: Outcomes, Prognostic Factors, and Clinical Implications from a Multicenter ICU Cohort

MedXY Editorial Team•Sep 2, 2026•Critical Care
septic shockAllogeneic Hematopoietic Stem Cell TransplantationICU outcomesprognostic factors

Highlight

  • Septic shock is a leading cause of ICU admission among allo-HSCT recipients, with a 63% mortality at 90 days.
  • Higher SOFA scores, fungal infections, and neutropenia independently predict poorer 90-day survival after septic shock.
  • Early aminoglycoside therapy correlates with improved short-term survival, though its causal role remains uncertain.
  • Age, graft-versus-host disease type, and early bacterial documentation do not independently affect 90-day mortality.

Study Background and Disease Burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Reevaluating Ventilation Rates During Pediatric CPR: New Insights into Age-Stratified OutcomesThis article explores findings from a multicenter study evaluating the impact of cardiopulmonary resuscitation ventilation rates on survival in pediatric intensive care, identifying age-specific ventilation targets linked to improved outcomOct 18, 2026Optimizing Early Resuscitation in Septic Shock: Balancing Fluids and VasopressorsA large randomized trial finds no difference in 90-day days alive and out of hospital between early vasopressors with restricted fluids versus higher fluids with delayed vasopressors in septic shock, though pulmonary edema was less frequentOct 16, 2026Age, Tumor Size, and Weight in Early-Stage Favorable Histology Wilms Tumor: Reevaluating Prognostic Indicators with COG DataThis pooled analysis from COG studies reveals that after accounting for tumor biology, age, tumor nephrectomy weight, and diameter are not independently predictive of outcomes in stage I/II favorable histology Wilms tumor, refining risk strOct 9, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Predicting Short-Term Outcomes in Pemphigus Patients Treated with Rituximab and Glucocorticoids: Insights from a Multicenter Chinese Cohort
This multicenter retrospective study identifies key baseline predictors influencing short-term remission and relapse in pemphigus patients treated with rituximab plus glucocorticoids, guiding personalized treatment strategies.
Oct 2, 2026
Transforming Care in Follicular Lymphoma: Outcomes and Prognostic Insights in the Rituximab EraThis study analyzes treatment patterns, outcomes, and prognostic factors in 344 patients with transformed follicular lymphoma in the rituximab era, revealing poor event-free survival but moderate overall survival and high relapse rates, guiSep 30, 2026
Divergent Roles of IL-12p40 and IL-18 in Severe Fibrosing Chronic Graft-versus-Host Disease: Implications for Immunity and Post-Transplant OutcomesThis study reveals distinct clinical associations of IL-12p40 and IL-18 in severe fibrosing chronic graft-versus-host disease, highlighting their differing impacts on relapse risk, survival, and immune responses post-allogeneic stem cell trAug 27, 2026